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Purpose. To assess whether intravitreal aflibercept (2.0mg) can effectively reduce persistent macular exudate and enhance visual
acuity in ranibizumab (0.5mg) and/or bevacizumab (1.25mg) treatment resistant patients with neovascular age-related macular
degeneration. Methods. This retrospective study included 47 treatment resistant eyes from 47 patients switched to intravitreal
aflibercept injections after receiving a minimum of 3 injections with either ranibizumab or bevacizumab. Snellen visual acuity
and optical coherence tomography were assessed just prior to the first injection (baseline) and prior to the fourth injection (final).
Additionally, anatomical regions of persistent macular exudate were tracked to determine if these areas yielded varying responses
to aflibercept. Results. At baseline, patients had received an average of 11.3 injections with any prior anti-VEGF drug (SD 5.96). For
whole group analysis, baseline and final central retinal thickness were 370.57𝜇m and 295.7 𝜇m (𝑃 ≤ .001), respectively. Baseline
and final retinal fluid volumes were 4.81mm3 and 4.37mm3 (𝑃 ≤ .001), respectively. Baseline and final logMAR were 0.56 and 0.53
(𝑃 = 0.301), respectively. Anatomic location of persistent exudate did not appreciably alter treatment outcome. Conclusion. Central
retinal thickness and total retinal fluid volume were reduced in ranibizumab and/or bevacizumab treatment resistant patients
following three aflibercept injections. No appreciable change in visual acuity was noted.
1. Introduction
Age-related macular degeneration, or AMD, is a leading
cause of blindness in America, as well as industrialized
countries worldwide, and it is estimated that nearly 10million
Americans suffer from AMD [1, 2]. Until recently there have
been two leading treatments for neovascular AMD which
inhibit vascular endothelial growth factor (VEGF) in order
to diminish choroidal neovascularization (CNV), namely,
ranibizumab (Lucentis, Genentech, Inc., South San Fran-
cisco, CA) and the off-label AMD therapeutic bevacizumab
(Avastin, Genentech, Inc., South San Francisco, CA). Both
drug therapies have been shown to effectively reduce vision
loss and potentially improve vision in many AMD patients
[3, 4]. Many studies have confirmed the outcomes and
risks of using either of these drugs for the treatment of
neovascular AMD and a majority of these studies, including
multicenter comparative clinical trials such as the CATT,
MANTA, GEFAL, and IVAN studies, have shown little to
no difference in outcomes of patients that are treated with
either drug [5–12]. Therefore, today both ranibizumab and
bevacizumab are recognized as efficacious therapeutics for
the treatment of neovascular AMD. Despite widely accepted
use of either drug, there remain many patients that display
persistent macular exudation posttreatment.
In November 2011, another inhibitory VEGF drug was
approved by the FDA for treatment of neovascular AMD,
namely, aflibercept (Eylea; Regeneron, Tarrytown, New York,
USA, and Bayer, Berlin, Germany). Aflibercept has been
shown to have a significantly higher binding affinity for
VEGF than either bevacizumab or ranibizumab [13]. The-
oretical calculations also suggest that a single aflibercept
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intravitreal injection would last between 48 and 83 days as
compared to only 30 days for a ranibizumab injection [14].
In phase III trials aflibercept was shown to be noninferior to
ranibizumab treatments and elicited the same outcome as a
monthly ranibizumab injection regimen when administered
bimonthly following 3 monthly injections over a 52-week
period [14, 15]. Consequently, aflibercept is being introduced
as a noninferior treatment option that requires fewer injec-
tions and is more affordable for patients.
Recently, a handful of studies have investigated the effects
of aflibercept on patients resistant to either bevacizumab or
ranibizumab therapy. Results from these studies are varied
with some reporting increased visual acuity (VA) following
aflibercept treatment in patients with persistent exudation, as
well as no change in VA posttreatment [16–19]. This current
study seeks to further define the clinical and anatomical
outcomes of aflibercept therapy in the previously treatment
resistant neovascular AMD population. This study also seeks
to determine if there is an association between anatomic
location of persistent choroidal exudation and response to
intravitreal aflibercept treatment in this same treatment
resistant population which is yet to be thoroughly discussed
in the literature.
2. Methods
Institutional review board approval was obtained from the
University of Central Florida. All patients selected for this ret-
rospective study were a subset of patients that had previously
qualified for the treatment of neovascular AMD and were at
least 55 years old. Inclusion criteria required that patients (1)
had to have been initially treated with either bevacizumab or
ranibizumab for the treatment of neovascular AMD with a
minimum of three intravitreal injections of either drug, (2)
had to be considered treatment resistant, excluding partial
responders that displayed persistent choroidal exudation
while receiving initial anti-VEGF therapy with either beva-
cizumab or ranibizumab, and (3) had to have received a base-
line visit that was recorded, being the visit immediately prior
to conversion to aflibercept therapy. Patients were excluded
from the study if (1) the OCT was dry at any time during the
three injections prior to conversion to aflibercept, (2) elapsed
time between prior treatment and the switch to aflibercept
exceeded 63 days, (3) following conversion to aflibercept ther-
apy the patient interrupted consecutive aflibercept treatment
with an alternative anti-VEGF therapy or any other interven-
tion for the treatment of AMD, and (4) they did not have at
least three aflibercept injections recorded after conversion.
Criteria for patient improvement during treatment with
bevacizumab and/or ranibizumab, and later with aflibercept
therapy, were determined by both optical coherence tomog-
raphy (OCT) and Snellen VA measurements. OCT images
were obtained using the Heidelberg Spectralis HRA+OCT
5.3.3.0 (Heidelberg Engineering, Inc., Vista, CA). Proprietary
algorithms, active eye tracking (TruTrack), and AutoRescan
were used to both accurately measure macular volume
and determine CRT. These features also allowed accurate
comparison of scans for a single patient using point-to-point
correspondence between scans.Macular volume asmeasured
by OCT was defined as total retinal fluid in this study. Also,
retinal scans were individually examined to determine the
anatomic location of fluid accumulation and subsequently
defined as intraretinal fluid (IRF), subretinal fluid (SRF), or
multiple layer fluid (MLF). VA was also collected with use of
a Snellen chart using best corrected visual acuity (BCVA). For
statistical purposes, Snellen VA values were converted into
logMAR. OCT and VA results reported and analyzed in this
study include those values obtained just prior to aflibercept
treatment (baseline) as well as those obtained just prior to
the 4th aflibercept injection (final). Other qualitative analyses
such as slit lamp and fundus examination were conducted.
At the initial patient encounter OCT and VA were con-
ducted to determine the status of the macula and patient
vision. Following a minimum of three injections of beva-
cizumab and/or ranibizumab, physicians changed patients to
aflibercept injections if there was persistent macular exuda-
tion. Following conversion to aflibercept therapy, OCT and
VA measurements continued to be obtained at every visit up
until just prior to the 4th aflibercept injection. These mea-
surements were first analyzed for the entire patient sample
which we refer to as whole group analysis. Following whole
group analysis, patients were further divided into subgroups
according to the anatomic location of persistentmacular exu-
dation mentioned earlier in order to determine whether any
of these regions had varying responses to intravitreal afliber-
cept therapy. Each subgroup was assessed using the same
methods as the whole group analysis.
Intravitreal injections were given to patients according to
Central Florida Retina and theMacular Degeneration Center
protocol. Topical anesthetic was applied and a sterile cotton
swab was soaked in sterile 4% lidocaine and applied numer-
ous times to the area receiving the injection. Patients were sit-
uated with a sterile lid speculum after which they were given
drops of povidone-iodine (5%) applied at least three times.
Injections were given using a 1mL tuberculin syringe with a
30-gauge needle. All injection doses for bevacizumab and ran-
ibizumab were 1.25mg and 0.5mg, respectively. Aflibercept
injections were given at a dose of 2mg.
Within-subject comparisons of continuous variables were
conducted usingWilcoxon signed ranks tests. 𝑃 values < 0.05
were considered statistically significant. Statistical analyses
were conducted using SPSS 20.0 (IBM; Chicago, IL). Power
analyses were conducted using G∗Power 3.1.3 [20].
3. Results
A total of 58 patients with persistent retinal fluid following
treatment with either bevacizumab or ranibizumab were
switched to 2.0mg aflibercept injections. Of these patients,
47 eyes (27 OD) from 47 patients met the inclusion criteria
described previously. Of this sample, 20 patients were male
and 27 female and average age was 80.5 years with a range
of 59–98 years (Table 1). Prior to aflibercept treatment,
this patient sample included 15 patients with exclusive
bevacizumab therapy which received an average of 10
injections (SD 5.29, range 3–22), 14 patients with exclusive
ranibizumab treatment with an average of 11.14 injections
(SD 7.14, range 3–26), and 18 patients that had received an
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Table 1: Baseline characteristics.
Total patients, 𝑛 47
Total eyes, 𝑛 (%) 47
Male, 𝑛 (%) 20 (42.6%)
Right eye, 𝑛 (%) 27 (57.4%)
Age, years (±SD, range) 80.5 (±8.02, 59–98)
Table 2: Injection history prior to aflibercept conversion.
Ranibizumab
Patients treated previously with only
ranibizumab, 𝑛 (%) 14 (29.8%)
Prior injections, mean (±SD, range) 11.14 (±7.14, 3–26)
Bevacizumab
Patients treated previously with only
bevacizumab, 𝑛 (%) 15 (31.9%)
Prior injections, mean (±SD, range) 10 (±5.29, 3–22)
Both
Patients treated previously with both, 𝑛 (%) 18 (38.3%)
Prior injections, mean (±SD, range) 12.5 (±5.57, 8–27)
All patients
Prior injections, mean (±SD, range) 11.3 (±5.96, 3–27)
Interval between 1st IVA and previous
anti-VEGF, days (±SD, range) 42.9 (±1.9, 27–63)
IVA, intravitreal aflibercept.
average of 12.5 injections of either drug (SD 5.57, range 8–27).
As a combined group, regardless of injection history, this
patient sample had received an average of 11.3 injections with
any prior anti-VEGF drug (SD 5.96, range 3–27).The average
interval between the last injection with a prior anti-VEGF
drug and the first aflibercept injection was 42.9 days (SD 1.9,
range 27–63) (Table 2).
Patients were first analyzed as an entire group in regard
to CRT, total retinal fluid volume, and VA (logMAR). Mean
CRT for the whole group analysis decreased by 74.9 𝜇m
with a baseline and final CRT of 370.57𝜇m (IQR 280.5–
428.5) and 295.7 𝜇m (IQR 232–335.5, 𝑃 ≤ .001), respectively.
Additionally, mean total retinal fluid decreased by 0.44mm3
following 3 aflibercept injections with a baseline and final
fluid volume of 4.81mm3 (IQR 3.06–7.6) and 4.37mm3 (IQR
2.82–7.18, 𝑃 ≤ .001), respectively. Baseline and final logMAR
for the group were 0.56 (IQR 0.29–0.99) or 20/73 and 0.53
(IQR 0.24–0.71, 𝑃 = 0.301) or 20/67, respectively (Table 3).
Following whole group analysis subgroups were analyzed.
Subgroup analysis revealed that, regardless of the ana-
tomic location of retinal fluid, there were statistically sig-
nificant reductions in both CRT and total retinal fluid for
all subgroups. Seven patients (14.9%) were found to have
persistent IRF.These patients had a baseline and final CRT of
422.29𝜇m (IQR 340.5–491.5) and 300.57 𝜇m (IQR 281–338,
𝑃 = 0.018), respectively. Baseline and final fluid volumes
for the IRF subgroup were 5.19mm3 (IQR 3.34–6.63) and
4.46mm3 (IQR 2.91–5.25, 𝑃 = 0.018) and baseline and
final logMAR were 0.90 (IQR 0.65–1.3) or 20/157 and 0.86
(IQR 0.51–1.02, 𝑃 = 0.596) or 20/146, respectively. 27
patients (57.4%) were classified as having persistent SRF.
These patients had a baseline and final CRT of 379.33 𝜇m
(IQR 294.5–417) and 309.48𝜇m (IQR 242.5–344, 𝑃 = 0.001),
respectively. Baseline and final fluid volumes were 4.62mm3
(IQR 3.03–6.79) and 4.25mm3 (IQR 2.81–5.39, 𝑃 = 0.007)
and baseline and final logMAR were 0.47 (IQR 0.27–0.63)
or 20/59 and 0.45 (IQR 0.21–0.57, 𝑃 = 0.692) or 20/56,
respectively. Finally, 9 patients (19.1%) were determined to
have persistentmultiple layer fluid persistence.These patients
had a baseline and final CRT of 360.33 𝜇m (IQR 271–425)
and 278𝜇m (IQR 232–307, 𝑃 = 0.021), respectively. Baseline
and final fluid volumes were 5.40mm3 (IQR 3.52–7.6) and
4.83mm3 (IQR 2.88–7.58, 𝑃 = 0.008) and baseline and final
logMAR were 0.48 (IQR 0.3–0.58) or 20/60 and 0.48 (IQR
0.28–0.52, 𝑃 = 0.933) or 20/60, respectively (Table 4).
The greatest reduction inCRT and total fluid volumewere
121.72 𝜇m and 0.73mm3, respectively, both of which were
seen in the IRF subgroup. VA findings were consistent with
those of the whole group analysis, showing either no change
in VA or slight increases of just more than 1-2 letters on a
Snellen chart. Again, these were not statistically significant.
Following three aflibercept injections whole group analysis
showed that 77% of patients experienced both a reduced
CRT and total retinal fluid volume (Figure 1). Many of these
patients showed changes following one aflibercept injection
(Figure 2).
4. Discussion
The treatment of neovascular AMD continues to progress
over time and the therapeutic options are becoming more
defined. This study indicates that an improved anatomical
outcome can be achieved in patients with persistent macular
exudation despite prior treatment with either ranibizumab
or bevacizumab following 3 aflibercept injections. This study
also indicates that, despite the anatomic region of persistent
macular exudation, CRT decreases in previously treatment
resistant patients when switched to aflibercept, something
that has not been explored in depth in the current literature.
In both the whole group and subgroup analysis there was no
clinically or statistically significant change in VA following
three aflibercept injections.
Even though aflibercept was able to resolve persistent
macular exudate in our patient sample it remains contro-
versial if a dry macula after anti-VEGF treatment allows for
regained VA. It may be that these treatment resistant patients
need more time once therapy has resolved macular exudate
before VA begins to improve. It was demonstrated in the
VIEWI and II trials that while aflibercept did show resolution
of macular exudation in treatment naı¨ve eyes earlier than
ranibizumab, there were no obvious gains in VA between
therapeutics after one year [15, 21, 22]. Moreover, patients in
this study received all three aflibercept injections and had all
visits recorded prior to an elapsed time of one full year with-
out appreciable increases in VA, which might suggest that
indeed more time is needed for an improved VA to become
apparent. At the conclusion of three aflibercept injections the
nonstatistically significant change in VA was a mean increase
of 0.03 logMAR, equivalent to just slightly more than a one
4 Journal of Ophthalmology
Table 3: Whole group anatomical and visual measurements following aflibercept.
Baseline mean (IQR) Final mean (IQR) 𝑃 value
Central retinal thickness (𝜇m) 370.57 (280.5–428.5) 295.7 (232–335.5) <0.001
Visual acuity (logMAR) 0.56 (0.29–0.99) 0.53 (0.24–0.71) 0.301
Total retinal fluid (mm3) 4.81 (3.06–7.6) 4.37 (2.82–7.18) <0.001
logMAR, logarithm of minimum angle of resolution.
IQR, interquartile range.
Table 4: Subgroup anatomical and visual measurements following aflibercept.
Baseline mean (IQR) Final mean (IQR) 𝑃 value
Persistent intraretinal fluid†
Central retinal thickness (𝜇m) 422.29 (340.5–491.5) 300.57 (281–338) 0.018
Visual acuity (logMAR) 0.90 (0.65–1.3) 0.86 (0.51–1.02) 0.596
Total retinal fluid (mm3) 5.19 (3.34–6.63) 4.46 (2.91–5.25) 0.018
Persistent subretinal fluid‡
Central retinal thickness (𝜇m) 379.33 (294.5–417) 309.48 (242.5–344) <0.001
Visual acuity (logMAR) 0.47 (0.27–0.63) 0.45 (0.21–0.57) 0.692
Total retinal fluid (mm3) 4.62 (3.03–6.79) 4.25 (2.81–5.39) 0.007
Persistent multiple layer fluid§
Central retinal thickness (𝜇m) 360.33 (271–425) 278 (232–307) 0.021
Visual acuity (logMAR) 0.48 (0.3–0.58) 0.48 (0.28–0.52) 0.933
Total retinal fluid (mm3) 5.40 (3.52–7.6) 4.83 (2.88–7.58) 0.008
†7 patients, ‡27 patients, and §9 patients.
logMAR, logarithm of minimum angle of resolution.
IQR, interquartile range.
(a) (b)
Figure 1: A patient with AMD previously treated with 14 ranibizumab injections and 13 bevacizumab injections shows persistent multilayer
fluid on OCT (a). Following three aflibercept injections (b) there was marked reduction in total fluid volume as well as a reduced CRT, 3.43
to 3.07mm3 and 405 to 293 𝜇m, respectively.
(a) (b)
Figure 2: A patient with AMD previously treated with 4 intravitreal ranibizumab injections shows persistent subretinal retinal fluid on OCT
(a). Following one intravitreal aflibercept injection (b) there was marked reduction of subretinal fluid and reduced CRT, 7.61 to 6.88mm3 and
442 to 223 𝜇m, respectively.
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letter gain on a Snellen chart. Similar insignificant findings
were also found to be the case for all subgroups evaluated
for changes in VA following aflibercept treatment. It may be
possible that neural damage secondary to AMD is extensive
enough in these patients that no appreciable VA will return.
The favorable response of patients with persistent exuda-
tion to aflibercept treatmentmay reasonably be attributed to a
number of explanations, including the molecular differences
that exist between anti-VEGF therapeutics. Bevacizumab is
a full length, humanized, recombinant monoclonal antibody
whereas ranibizumab is an affinity matured, humanized,
monoclonal antibody Fab fragment [23]. The original devel-
opment of these two anti-VEGF drugs was aimed at slightly
different therapeutic approaches. Bevacizumab was designed
with the intent to treat systemic, advanced cancers whereas
ranibizumab was designed as a Fab fragment with the intent
to allow its 49 kD size to penetrate the 79 kD retinal exclusion
limit [24]. Yet despite these subtle differences their outcomes
have been shown in manymulticenter trials to be near equiv-
alent as both bevacizumab and ranibizumab effectively target
and inhibit the receptor binding domains of all VEGF-A
isoforms. In contrast, aflibercept is a soluble decoy fusion pro-
tein capable of binding all VEGF-A and VEGF-B isoforms, as
well as placental growth factor, with greater affinity than other
anti-VEGF therapeutics currently available [24, 25]. Also, as
discussed earlier, theoretical calculations have estimated that
a single aflibercept intravitreal injection lasts between 48
and 83 days as compared to only 30 days for a ranibizumab
injection [10]. Although intraocular half-life of aflibercept
in humans has not been confirmed, these calculations, in
addition to aflibercept’s stronger binding affinity and broader
selectivity, offer a reasonable explanation as to how it has
been efficacious in reducing both CRT and total fluid volume
in the treatment resistant macula. Another alternative may
be that tachyphylaxis occurs due to the nature of frequent
dosing with bevacizumab or ranibizumab. It is important to
note that some patients in this study had received as many
as 27 injections of any anti-VEGF therapeutic before the
switch to aflibercept. Also, the question remains as towhether
patients that were once treatment resistant and who are now
currently treated with aflibercept and experiencing improved
anatomical outcomes will eventually become tachyphylactic
to aflibercept.
Results from this study, and others, raise the important
question regarding the need to justify time consuming and
costly treatment with anti-VEGF therapy, particularly in non-
responders converted to aflibercept, when there is improved
macular exudate but no gains inVA.While it is true that there
was no statistically significant improvement inVA it is impor-
tant to note that there was also no statistical decline in VA.
Anti-VEGF therapeutics, even when treatment resistant eyes
are switched to aflibercept, still serve the purpose of bringing
disease progression to a standstill in most patients with
neovascular AMD. The potential for aflibercept to restore
VA in treatment resistant eyes is also currently under much
investigation and while this study shows no improvement
in VA, others have found increased visual outcomes for
treatment resistant patients switched to aflibercept [16]. As
discussed earlier, it is critical to further understand if patients
needmore timewith aflibercept treatment before a gain inVA
is noted. One thing seems sure: more research is necessary in
order to come to any certain conclusion regarding the need
for aflibercept treatment in ranibizumab and/or bevacizumab
nonresponders.
While our evaluation of persistent macular exudate by
anatomic region did reveal that CRT is reduced in response
to aflibercept despite anatomic region in all subgroups it
is important to recognize that our patient subgroups were
small due to inclusion criteria. Future studies might evaluate
larger groups of patients with specific retinal fluid lesions,
including intraretinal, subretinal, and subpigment epithelial
fluid persistence to further define the results of this study.
Results concerning VA for these same subgroups may be
further defined with an increased sample size.
Limitations of this study include a small sample size,
longer than desired time period between converting to afli-
bercept from prior anti-VEGF therapy, retrospective design,
lack of a control arm, time span of only three aflibercept injec-
tions, and the use of Snellen VA. Ideally, time of converting
from a previous anti-VEGF to aflibercept would have been
no more than an average of 30 days with exclusion criteria
set at maximum 45 days. We chose to extend our exclusion
criterion to 63 days in order to have a sufficient population
to ensure reliable data. As a retrospective, uncontrolled study
assessing a patient population treated by multiple retinal spe-
cialists there inherently are constraints on data interpretation.
Although this study did not include additional injections
beyond three aflibercept treatments the original intent was to
see if there were marked changes in VA or macular exudate
in the immediate period of aflibercept treatment. While this
study indicates that there was no appreciable change in VA,
some caution should be taken in regard to VA analysis as it
has been shown that Early Treatment Diabetic Retinopathy
Study (ETDRS) charts aremore accurate in assessing VA than
Snellen charts, particularly with poor VA populations [26].
In conclusion, this research study shows that following
three intravitreal aflibercept injections in exudate persistent
neovascular AMD patients there is marked reduction of CRT
and total retinal fluid volume as seen onOCT, with amajority
of patients (77%) having a favorable anatomic response. This
study also shows that both a reduced CRT and total retinal
fluid volume can be achieved in exudate persistent patients
regardless of the anatomic location of exudation in the retina,
specifically IRF, SRF, and MLF. No clinically or statistically
significant changes in VA were noted.
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